Idalopirdine-rivastigmine
butyrylcholinesterase inhibitor and 5-HT6 receptor antagonist. BuChE (IC50 = 0.97 microM). After hydrolysis a potent 5-HT6 receptors antagonist (Ki = 11.4 nM) related to idalopirdine is released
General
Type : Drug,Pro-Drug,Carbamate,Derivative of Rivastigmine,Multitarget,5-HT-receptor-ligand
Chemical_Nomenclature :
Canonical SMILES : C1(=C[N]C2=CC(=CC=C12)F)CCNCC3=CC(=CC=C3)OC(=O)N(C)CC
InChI : InChI=1S\/C21H24FN3O2\/c1-3-25(2)21(26)27-18-6-4-5-15(11-18)13-23-10-9-16-14-24-20-12-17(22)7-8-19(16)20\/h4-8,11-12,14,23-24H,3,9-10,13H2,1-2H3
InChIKey : QZGAFMLTVWNDEJ-UHFFFAOYSA-N
Other name(s) : CHEMBL4744490,BDBM50562650,PD168472
MW : 369.43 || 369.4
Formula : C21H24FN3O2
CAS_number :
PubChem : 162648336
UniChem : QZGAFMLTVWNDEJ-UHFFFAOYSA-N
IUPHAR :
Wikipedia :
Target
Families : Idalopirdine-rivastigmine ligand of proteins in family: BCHE
Stucture :
Protein : human-BCHE
References (1)
| Title : Pleiotropic prodrugs: Design of a dual butyrylcholinesterase inhibitor and 5-HT(6) receptor antagonist with therapeutic interest in Alzheimer's disease - Toublet_2020_Eur.J.Med.Chem_210_113059 |
| Author(s) : Toublet FX , Lalut J , Hatat B , Lecoutey C , Davis A , Since M , Corvaisier S , Freret T , Sopkova-de Oliveira Santos J , Claeysen S , Boulouard M , Dallemagne P , Rochais C |
| Ref : Eur Journal of Medicinal Chemistry , 210 :113059 , 2020 |
| Abstract : Toublet_2020_Eur.J.Med.Chem_210_113059 |
| ESTHER : Toublet_2020_Eur.J.Med.Chem_210_113059 |
| PubMedSearch : Toublet_2020_Eur.J.Med.Chem_210_113059 |
| PubMedID: 33310288 |